TICKERNERD
Menu
TEMTEMHealthcare · Health Information Services

TEM Stock Forecast: Tempus AI, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$80
+14.85% on the day

The 19 Wall Street analysts covering Tempus AI, Inc. hold a median 12-month price target of $70 — -12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 17 Sept 2026 — in the weakest quartile.

Market cap
$12.4B
Ticker Nerd rank
24 / 100
Median analyst target
$70
Analysts covering
19
Revenue$382.5M+21.6% y/y
Operating income−$75.9M
Net income$5.6M
Free cash flow−$18.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+36.8%
1M
+55.6%
YTD
+36.1%
1Y
−7.0%
From 52W high
−22.2%
From 52W low
+93.4%
$42
$103
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempus AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
77
Quality
54
Value
48
Growth
47
Momentum
37
Accruals
23
Issuance
16
Volatility
15
Size
12

Revisions (77): Analysts have, on balance, been raising their forecasts.

Volatility (15): The share price moves around a lot.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Oct 25Jan 26Apr 26Jul 26TEMHigh $100Median $70Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
10 Buy8 Hold1 Sell
Low $35Median $70High $100

The green dot is the last close — the median target sits −12.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
11 Sept 2026HC Wainwright & Co.MaintainsBuy$56 → $66
9 Sept 2026UBSInitiatesNeutral$70
8 Sept 2026Roth CapitalInitiatesNeutral$67
8 Sept 2026Rothschild & CoInitiatesNeutral$67
2 Sept 2026Cantor FitzgeraldInitiatesOverweight$80
2 Sept 2026Cantor FitzgeraldInitiatesOverweight—
1 Sept 2026Piper SandlerUpgradeOverweight$56 → $76
1 Sept 2026Piper SandlerUpgradeOverweight—
31 Aug 2026Freedom Capital MarketsMaintainsHold$51 → $73
31 Aug 2026Freedom Capital MarketsMaintainsHold—
20 Aug 2026BTIGMaintainsBuy$70 → $80
20 Aug 2026BTIGMaintainsBuy—
4 Aug 2026Piper SandlerMaintainsNeutral—
4 Aug 2026Piper SandlerMaintainsNeutral$58 → $56
3 Aug 2026BTIGMaintainsBuy—
3 Aug 2026BTIGMaintainsBuy$80 → $70
3 Aug 2026HC Wainwright & Co.MaintainsBuy$64 → $56
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026StifelMaintainsHold$60 → $50
3 Aug 2026StifelMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TEM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Tempus AI, Inc. returned −7.0% against +17.0% for the S&P 500, dividends included.

TEM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26TEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
1
Fundamentals

Tempus AI, Inc. (TEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.3×

Cheaper than 19% of US stocks

Price / sales
8.7×

Cheaper than 16% of US stocks

Price / book
27.9×

Cheaper than 3% of US stocks

EV / EBITDA
−67.5×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
21.6%

Higher than 71% of US stocks

Earnings growth (YoY)
21.6%

Higher than 60% of US stocks

Gross margin
64.4%

Higher than 78% of US stocks

Operating margin
−20.1%

Higher than 21% of US stocks

Net margin
−17.8%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−67.4%

Higher than 18% of US stocks

Return on assets
−8.5%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tempus AI, Inc. (TEM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tempus AI, Inc. has a market value of $12.4B and an enterprise value of $13.1B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 21.6% year on year.

  • Net income over the same four quarters: −$254.4M, a −17.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$273.0M, after $9.8M of capital spending.

  • Shares outstanding: 180.2M.

  • Trailing P/E: 39.3×; forward P/E: 17212.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tempus AI, Inc. employs 3,800 people — $377K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Sept 2026

Data provided by Twelve Data

Peers

TEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
TEMTempus AI, Inc.$12.4B
24
BTSGBrightSpring Health Services, Inc.$11.0B
91
HQYHealthEquity, Inc.$8.1B
94
HNGEHinge Health, Inc.$7.3B
79
WAYWaystar Holding Corp.$5.1B
34
DOCSDoximity, Inc.$4.9B
61
VEEVVeeva Systems, Inc.$43.4B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempus AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TEM news & analysis

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

24/7 Wall Street · 17 Sept 2026positive

Tempus AI shares rallied roughly 30% this week after Morgan Stanley remarks on September 15 highlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. The bank's comments boosted its revenue outlook for the company.

Why it matters — A TEM watcher would care because improved reimbursement-driven revenue expectations from a major bank suggest growing commercial momentum for the diagnostics company.

Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Tempus AI, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the transcript of the presentation was published by Seeking Alpha. The item records the company's participation in the event.

Why it matters — A TEM watcher would care because the presentation transcript offers direct insight into management's current statements and positioning at a major industry conference.

Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI

CNBC Television · 14 Sept 2026positive

Tempus AI founder and CEO Eric Lefkofsky appeared on CNBC's 'The Exchange' to discuss AI's role in healthcare, stating that healthcare will likely be the biggest beneficiary of AI. He also discussed advancing cancer research with AI and personalized vaccines.

Why it matters — The CEO's public endorsement of healthcare as AI's biggest beneficiary could raise investor attention on Tempus AI's core mission and positioning.

REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine

Fox Business · 12 Sept 2026positive

Tempus CEO Eric Lefkofsky discussed the company's AI-driven precision medicine partnership with Merck on Fox Business's "The Claman Countdown." The segment highlighted Tempus's use of artificial intelligence in healthcare, clinical data, and patient care.

Why it matters — A TEM watcher would care because the Merck partnership and its prominent media coverage highlight Tempus's role in AI-driven precision medicine and its visibility in the healthcare technology space.

Nvidia, Snowflake, Chubb And A Health Care Stock On CNBC's ‘Final Trades'

Benzinga · 11 Sept 2026neutral

On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management selected Snowflake Inc., while the segment also featured Nvidia, Chubb, and a health care stock. The excerpt focuses on these picks and does not mention Tempus AI.

Why it matters — A TEM watcher would care because the health care stock mentioned in the segment may relate to the sector in which Tempus AI operates, though Tempus itself is not referenced.

FAQ

Frequently asked questions about TEM stock

What is the TEM stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Tempus AI, Inc. have a median 12-month price target of $70, with estimates ranging from $35 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TEM stock a buy right now?

Of the 19 analysts covering Tempus AI, Inc., 10 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tempus AI, Inc. 24 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TEM?

As at 17 Sept 2026, Tempus AI, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).

Will TEM stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies -12.9% from the last close, and Ticker Nerd's factor model ranks Tempus AI, Inc. 24 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TEM stock forecast for 2030?

No analyst covering Tempus AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $100 over the next 12 months.

How has TEM stock performed over the past year?

Tempus AI, Inc. returned -7.0% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tempus AI, Inc. do?

Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development.

What is the latest news on TEM?

The most recent item we track (24/7 Wall Street, 17 Sept 2026): "Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook". Tempus AI shares rallied roughly 30% this week after Morgan Stanley remarks on September 15 highlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. The bank's comments boosted its revenue outlook for the company.

Company

About Tempus AI, Inc.

Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.

CEO Mr. Eric P. Lefkofsky J.D. · 3,800 employees · United States · https://www.tempus.com